CVKD
Cadrenal Therapeutics, Inc.
Price Chart
Latest Quote
$0.94
+0.03 (+3.55%)
Current Price
| Previous Close | $0.91 |
| Open | $0.90 |
| Day High | $0.99 |
| Day Low | $0.86 |
| Volume | 60,380 |
Stock Information
| Shares Outstanding | 3.57M |
| Cash Equivalents | $2.39M |
| Net Income | $-11.54M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.36M |
| EPS (TTM) | $-4.91 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $974K |
| Income | $-11.54M |
| Book/sh | $1.32 |
| Cash/sh | $0.67 |
| Employees | 5 |
Financial Ratios
| Quick Ratio | 3.39 |
| Current Ratio | 3.73 |
Returns & Margins
| ROA | -125.93% |
| ROE | -275.16% |
Ownership
| Insider Ownership | 9.66% |
| Institutional Ownership | 10.35% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.28 |
| P/B | 0.71 |
Analyst Data
| Recommendation | none |
| Target Price | $14.00 |
Technical Indicators
| SMA20 | $0.98 |
| SMA50 | $1.18 |
| SMA200 | $4.06 |
| RSI | 47.62 |
| ATR | 0.1068 |
| Shares Float | 3.22M |
| Short Float | 8.80% |
| Short Ratio | 1.37 |
| Volatility | 1.95 |
| Rel Volume | 0.29 |
Performance History
| Week | -9.42% |
| Month | -15.89% |
| Quarter | -52.18% |
| 6 Months | -82.33% |
| YTD | -87.15% |
| Year | -93.34% |
| 3 Years | -88.06% |
| 10 Years | -98.48% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $0.94 | 60,400 |
| 2026-10-26 | $0.91 | 52,200 |
| 2026-10-23 | $0.96 | 38,200 |
| 2026-10-22 | $0.97 | 19,800 |
| 2026-10-21 | $1.02 | 28,200 |
| 2026-10-20 | $1.04 | 48,700 |
| 2026-10-19 | $1.06 | 152,200 |
| 2026-10-16 | $1.09 | 173,200 |
| 2026-10-15 | $0.97 | 104,200 |
| 2026-10-14 | $1.02 | 344,300 |
| 2026-10-13 | $1.00 | 376,400 |
| 2026-10-12 | $0.87 | 111,400 |
| 2026-10-09 | $0.91 | 82,400 |
| 2026-10-08 | $0.93 | 311,200 |
| 2026-10-07 | $0.97 | 1,781,700 |
| 2026-10-06 | $0.99 | 98,000 |
| 2026-10-05 | $0.95 | 63,000 |
| 2026-10-02 | $0.94 | 149,600 |
| 2026-10-01 | $0.97 | 109,200 |
| 2026-09-30 | $1.08 | 21,700 |
| 2026-09-29 | $1.09 | 38,200 |
| 2026-09-28 | $1.12 | 75,600 |
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
đ° Latest News
No news articles available at the moment. Check back later for updates on CVKD.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 |
| Expenses | |||
| Total Expenses | $13,461,177 | $10,960,619 | $7,632,843 |
| Net Non Operating Interest Income Expense | $223,815 | $309,251 | $231,991 |
| Operating Expense | $13,461,177 | $10,960,619 | $7,632,843 |
| General And Administrative Expense | $9,354,135 | $6,753,726 | $3,549,514 |
| Interest Expense | - | $0 | $17,101 |
| Interest Expense Non Operating | - | $0 | $17,101 |
| Other Income Expense | - | - | $-956,234 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-13,237,362 | $-10,651,368 | $-8,357,086 |
| Net Interest Income | $223,815 | $309,251 | $231,991 |
| Interest Income | $223,815 | $309,251 | $249,092 |
| Normalized Income | $-13,237,362 | $-10,651,368 | $-7,400,852 |
| Net Income From Continuing And Discontinued Operation | $-13,237,362 | $-10,651,368 | $-8,357,086 |
| Total Operating Income As Reported | $-13,461,177 | $-10,960,619 | $-7,632,843 |
| Net Income Common Stockholders | $-13,237,362 | $-10,651,368 | $-8,357,086 |
| Net Income | $-13,237,362 | $-10,651,368 | $-8,357,086 |
| Net Income Including Noncontrolling Interests | $-13,237,362 | $-10,651,368 | $-8,357,086 |
| Net Income Continuous Operations | $-13,237,362 | $-10,651,368 | $-8,357,086 |
| Pretax Income | $-13,237,362 | $-10,651,368 | $-8,357,086 |
| Interest Income Non Operating | $223,815 | $309,251 | $249,092 |
| Operating Income | $-13,461,177 | $-10,960,619 | $-7,632,843 |
| Depreciation Amortization Depletion Income Statement | $6,874 | $1,880 | $1,980 |
| Depreciation And Amortization In Income Statement | $6,874 | $1,880 | $1,980 |
| Depreciation Income Statement | $6,874 | $1,880 | $1,980 |
| Special Income Charges | - | $0 | $-740,139 |
| Per Share | |||
| Diluted EPS | $-6.64 | $-8.73 | $-9.29 |
| Basic EPS | $-6.64 | $-8.73 | $-9.29 |
| Other | |||
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-13,454,303 | $-10,958,739 | $-7,381,771 |
| Reconciled Depreciation | $6,874 | $1,880 | $1,980 |
| EBITDA (Bullshit earnings) | $-13,454,303 | $-10,958,739 | $-8,338,005 |
| EBIT | $-13,461,177 | $-10,960,619 | $-8,339,985 |
| Diluted Average Shares | $1,993,757 | $1,219,550 | $899,465 |
| Basic Average Shares | $1,993,757 | $1,219,550 | $899,465 |
| Diluted NI Availto Com Stockholders | $-13,237,362 | $-10,651,368 | $-8,357,086 |
| Research And Development | $4,100,168 | $4,205,013 | $4,081,349 |
| Selling General And Administration | $9,354,135 | $6,753,726 | $3,549,514 |
| Other Gand A | $9,354,135 | $6,753,726 | $3,549,514 |
| Total Unusual Items | - | $0 | $-956,234 |
| Total Unusual Items Excluding Goodwill | - | $0 | $-956,234 |
| Other Special Charges | - | - | $740,139 |
| Gain On Sale Of Security | - | - | $-216,095 |
Fetched: 2026-10-11
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,738,726 | $7,439,575 | $7,692,375 | $-5,551,150 |
| Total Assets | $4,326,708 | $10,123,533 | $8,519,250 | $778,174 |
| Total Non Current Assets | $7,341 | $10,736 | $27,077 | $50,578 |
| Other Non Current Assets | $2,167 | $3,792 | $3,792 | $5,987 |
| Current Assets | $4,319,367 | $10,112,797 | $8,492,173 | $727,596 |
| Other Current Assets | $200,140 | $42,257 | $52,425 | $22,715 |
| Current Deferred Assets | $106,342 | $14,445 | $0 | $672,295 |
| Receivables | $5,096 | $38,153 | $37,248 | - |
| Accrued Interest Receivable | $5,096 | $38,153 | $37,248 | - |
| Cash Cash Equivalents And Short Term Investments | $4,007,789 | $10,017,942 | $8,402,500 | $32,586 |
| Cash And Cash Equivalents | $4,007,789 | $10,017,942 | $8,402,500 | $32,586 |
| Prepaid Assets | - | $42,257 | $52,425 | $22,715 |
| Cash Financial | - | - | - | $32,586 |
| Debt | ||||
| Total Debt | - | $0 | $21,350 | $640,706 |
| Long Term Debt And Capital Lease Obligation | - | - | $0 | $574,690 |
| Current Debt And Capital Lease Obligation | - | - | $21,350 | $66,016 |
| Net Debt | - | - | - | $564,482 |
| Long Term Debt | - | - | - | $553,340 |
| Current Debt | - | - | - | $43,728 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,587,982 | $2,683,958 | $826,875 | $6,329,324 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $4,994,847 |
| Current Liabilities | $1,587,982 | $2,683,958 | $826,875 | $1,334,477 |
| Payables And Accrued Expenses | $854,786 | $1,717,383 | $209,394 | $663,171 |
| Payables | $650,663 | $1,502,468 | $167,319 | $404,897 |
| Accounts Payable | $650,663 | $1,502,468 | $167,319 | $404,897 |
| Derivative Product Liabilities | - | - | $0 | $4,379,944 |
| Current Notes Payable | - | - | $0 | $43,728 |
| Equity | ||||
| Common Stock Equity | $2,738,726 | $7,439,575 | $7,692,375 | $-5,551,150 |
| Total Equity Gross Minority Interest | $2,738,726 | $7,439,575 | $7,692,375 | $-5,551,150 |
| Stockholders Equity | $2,738,726 | $7,439,575 | $7,692,375 | $-5,551,150 |
| Retained Earnings | $-38,960,145 | $-25,722,783 | $-15,071,415 | $-6,714,329 |
| Other | ||||
| Ordinary Shares Number | $2,338,127 | $1,782,486 | $868,183 | $775,638 |
| Share Issued | $2,338,127 | $1,782,486 | $868,183 | $775,638 |
| Tangible Book Value | $2,738,726 | $7,439,575 | $7,692,375 | $-5,551,150 |
| Invested Capital | $2,738,726 | $7,439,575 | $7,692,375 | $-4,954,082 |
| Working Capital | $2,731,385 | $7,428,839 | $7,665,298 | $-606,881 |
| Total Capitalization | $2,738,726 | $7,439,575 | $7,692,375 | $-4,997,810 |
| Additional Paid In Capital | $41,696,533 | $33,160,576 | $22,762,922 | $1,154,985 |
| Capital Stock | $2,338 | $1,782 | $868 | $8,194 |
| Common Stock | $2,338 | $1,782 | $868 | $8,194 |
| Preferred Stock | $0 | $0 | $0 | - |
| Pensionand Other Post Retirement Benefit Plans Current | $733,196 | $966,575 | $596,131 | $605,290 |
| Current Accrued Expenses | $204,123 | $214,915 | $42,075 | $258,274 |
| Net PPE | $5,174 | $6,944 | $23,285 | $44,591 |
| Gross PPE | $5,174 | $6,944 | $23,285 | $44,591 |
| Other Properties | $5,174 | $6,944 | $23,285 | $44,591 |
| Capital Lease Obligations | - | $0 | $21,350 | $43,638 |
| Current Capital Lease Obligation | - | $0 | $21,350 | $22,288 |
| Non Current Accrued Expenses | - | - | $0 | $40,213 |
| Long Term Capital Lease Obligation | - | - | $0 | $21,350 |
Fetched: 2026-10-11
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-12,606,770 | $-7,364,087 | $-3,533,577 |
| Operating Activities | |||
| Operating Cash Flow | $-12,601,666 | $-7,357,550 | $-3,530,323 |
| Cash Flow From Continuing Operating Activities | $-12,601,666 | $-7,357,550 | $-3,530,323 |
| Operating Gains Losses | - | - | $956,234 |
| Investing Activities | |||
| Capital Expenditure | $-5,104 | $-6,537 | $-3,254 |
| Investing Cash Flow | $-5,104 | $-6,537 | $-3,254 |
| Cash Flow From Continuing Investing Activities | $-5,104 | $-6,537 | $-3,254 |
| Financing Activities | |||
| Repurchase Of Capital Stock | $-291,883 | $0 | - |
| Issuance Of Capital Stock | $7,159,714 | $5,143,594 | $11,903,491 |
| Financing Cash Flow | $6,596,617 | $8,979,529 | $11,903,491 |
| Cash Flow From Continuing Financing Activities | $6,596,617 | $8,979,529 | $11,903,491 |
| Net Other Financing Charges | $-271,214 | $-878,661 | - |
| Net Common Stock Issuance | $6,867,831 | $5,143,594 | $11,903,491 |
| Common Stock Issuance | $7,159,714 | $5,143,594 | $11,903,491 |
| Other | |||
| End Cash Position | $4,007,789 | $10,017,942 | $8,402,500 |
| Beginning Cash Position | $10,017,942 | $8,402,500 | $32,586 |
| Changes In Cash | $-6,010,153 | $1,615,442 | $8,369,914 |
| Proceeds From Stock Option Exercised | $0 | $4,714,596 | $250,000 |
| Common Stock Payments | $-291,883 | $0 | - |
| Net PPE Purchase And Sale | $-5,104 | $-6,537 | $-3,254 |
| Purchase Of PPE | $-5,104 | $-6,537 | $-3,254 |
| Change In Working Capital | $-1,311,074 | $1,873,251 | $144,309 |
| Change In Other Working Capital | $-91,897 | $-14,445 | $672,295 |
| Change In Other Current Assets | $1,625 | $0 | $2,195 |
| Change In Payables And Accrued Expense | $-1,095,976 | $1,878,433 | $-463,223 |
| Change In Accrued Expense | $-244,171 | $543,284 | $-225,645 |
| Change In Payable | $-851,805 | $1,335,149 | $-237,578 |
| Change In Account Payable | $-851,805 | $1,335,149 | $-237,578 |
| Change In Prepaid Assets | $-157,883 | $10,168 | $-29,710 |
| Change In Receivables | $33,057 | $-905 | $-37,248 |
| Stock Based Compensation | $1,939,896 | $1,419,039 | $710,381 |
| Depreciation Amortization Depletion | $6,874 | $1,880 | $1,980 |
| Depreciation And Amortization | $6,874 | $1,880 | $1,980 |
| Depreciation | $6,874 | $1,880 | $1,980 |
| Net Income From Continuing Operations | $-13,237,362 | $-10,651,368 | $-8,357,086 |
| Repayment Of Debt | - | $0 | $-250,000 |
| Net Issuance Payments Of Debt | - | $0 | $-250,000 |
| Net Short Term Debt Issuance | - | $0 | $-250,000 |
| Short Term Debt Payments | - | $0 | $-250,000 |
| Other Non Cash Items | - | $-352 | $3,013,859 |
| Issuance Of Debt | - | - | $0 |
| Net Long Term Debt Issuance | - | - | $0 |
| Long Term Debt Issuance | - | - | $0 |
| Change In Interest Payable | - | - | $0 |
| Gain Loss On Investment Securities | - | - | $216,095 |
Fetched: 2026-10-11